Agrisera

Agrisera AB is a Swedish biotechnology company specializing in the production of polyclonal and monoclonal antibodies, with a particular emphasis on plant and algal cell biology. Established in 1985, Agrisera has grown to become a leading supplier of antibodies for plant research, offering a comprehensive catalog of ready-made antibodies primarily targeting plant and algal proteins.

The company's product portfolio includes over 800 primary antibodies and more than 2,000 secondary antibodies suitable for various applications and available in multiple quantities. These products are meticulously designed and validated to ensure high specificity and performance in research applications.

Agrisera's commitment to quality and customer support is reflected in its experienced scientific staff, who are readily available to assist researchers in selecting the appropriate antibodies and troubleshooting experimental challenges. This dedication has earned Agrisera recognition in the scientific community, including being named the Plant Science Antibody Supplier of the Year in 2019 by CiteAb.

In 2020, Agrisera was acquired by Olink, a company known for its Proximity Extension Assay (PEA) technology used in protein biomarker research. Subsequently, in July 2024, Thermo Fisher Scientific acquired Olink, integrating Agrisera into its extensive portfolio of life science research tools.

Browse Agrisera Products

1 | PEB (4x) | protein extraction buffer

SKU: AS08 300|Size: 5x 2 mL (4x Stock)

3-hydroxybutyrate dehydrogenase, Affinity purified

SKU: AS09 564|Size: 1 mg

3-hydroxybutyrate dehydrogenase, Biotin conjugated

SKU: AS09 563|Size: 10 mg

A set of 7 antibodies against SOD1 | superoxide dismutase 1, soluble

SKU: AS09 578set|Size: 100 µL

A-I | apolipoprotein A1

SKU: AS10 1353|Size: 1 mg

A1AGP | Alpha-1-acid glycoprotein

SKU: AS01 015|Size: 200 µL

A1M | Human alpha-1-microglobulin

SKU: AS13 2670|Size: 100 µg

A1i3 | alpha-1-inhibitor 3

SKU: AS07 272|Size: 200 µg

ABA tracer (alkaline phospahatase conjugated)

SKU: AS10 726|Size: 1000 Assays

ABA | Abscisic acid ELISA quantitation kit (5x96T)

SKU: AS20 4392-5x96|Size: 1 Each

ABA | Abscisic acid ELISA quantitation kit (96T)

SKU: AS20 4392|Size: 1 Each

ABA | Abscisic acid ELISA quantitation trial kit (24T)

SKU: AS20 4392-24|Size: 1 Each

ABI4 | Abscisic acid insensitive 4

SKU: AS16 3989|Size: 50 µg

ACCase subunit beta | Acetyl-coenzyme A, carboxylase (subunit beta)

SKU: AS15 2880|Size: 100 µL

ACT | Actin (monoclonal, clone 14H4G8), 10 µg

SKU: AS21 4615-10|Size: 10 µg

ACT | Actin (protein)

SKU: AS16 4111S|Size: 100 µg

AFP | alpha-fetoprotein

SKU: AS10 1378|Size: 1 mg

AGO, Argonaute set | 4 antibodies

SKU: AS18 4248|Size: 1 Each

AGO1 | Argonaute 1, Blocking peptide

SKU: AS09 527P|Size: 100 µg

AGRP | agouti related protein

SKU: AS13 2687|Size: 50 µL

AHSG | alpha-2-HS glycoprotein

SKU: AS10 1367|Size: 1 mg

AKIN ß gamma

SKU: AS09 463|Size: 50 µg

AKIN10 | SNF1-related protein kinase catalytic subunit alpha KIN10

SKU: AS10 919|Size: 100 µg

AMBP | Alpha-1-microglobulin

SKU: AS01 014|Size: 200 µL

AMBP | Bikunin

SKU: AS04 039|Size: 200 µL

AMBP | Bikunin (50 µl)

SKU: AS06 173|Size: 50 µL

AMBP | Bikunin (mice)

SKU: AS04 040|Size: 200 µL

AOX | AOX positive control/quantitation standard

SKU: AS04 054S|Size: 120 µL

APOA2 | apolipoprotein A-II

SKU: AS10 1391|Size: 1 mg

APOB | apolipoprotein B

SKU: AS10 1359|Size: 1 mg

APOE | apolipoprotein E

SKU: AS10 1309|Size: 1 mg

APase | acid phosphatase

SKU: AS09 520|Size: 1 mg

APase | acid phosphatase, Biotin conjugated

SKU: AS09 541|Size: 10 mg

ASNA1 | Arsenical pump-driving ATPase

SKU: AS08 288|Size: 200 µL

AT | antithrombin III

SKU: AS10 1345|Size: 1 mg

ATG5 | Autophagy protein 5 (human)

SKU: AS13 2695|Size: 100 µL

ATG7 | Autophagy-related protein 7 (human)

SKU: AS13 2699|Size: 100 µL

Aflatoxin B1 | ELISA quantitation kit

SKU: AS20 4397|Size: 1 Each

Aflatoxin B1, Serum (0,1 ml)

SKU: AS11 1662|Size: 0.1 mL

Aflatoxin B1, Serum (1 ml)

SKU: AS11 1640|Size: 1 mL

Aflatoxin B1, Total IgG (0,5 mg)

SKU: AS11 1733|Size: 0.5 mg

Aflatoxin B1, Total IgG (2,5 mg)

SKU: AS11 1682|Size: 2.5 mg

Aflatoxin M1 | ELISA quantitation kit

SKU: AS20 4394|Size: 1 Each

Aflatoxin M1, Serum (1 ml)

SKU: AS11 1741|Size: 1 mL

AgriCoat-Block | Non mammalian Protein Coat Block (5X)

SKU: AS18 AgriCtBlock-100mL|Size: 10 mL 100 mL 1L

AgriCoat-Block | Non mammalian Protein Coat Block (5X) (10 ml)

SKU: AS18 AgriCtBlock-10|Size: 10 mL

AgriCoat-Block | Non mammalian Protein Coat Block (5X) (100 ml)

SKU: AS18 AgriCtBlock-100|Size: 100 mL

AgriCoat-Block | Non mammalian Protein Coat Block (5X) (1L ml)

SKU: AS18 AgriCtBlock-1L|Size: 1 L

Agrisera BCIP/NBT ALP Substrate (100 ml)

SKU: AS19 BCIP-NBT-100|Size: 100 mL

Agrisera BCIP/NBT ALP Substrate (1000 ml)

SKU: AS19 BCIP-NBT-1000|Size: 100 mL 1000 mL

Agrisera BCIP/NBT ALP Substrate (1L)

SKU: AS19 BCIP-NBT-1L|Size: 1000 mL

Agrisera BCIP/NBT Plus ALP Substrate (100 ml)

SKU: AS19 BCIPNBTPLUS-100|Size: 100 mL

Agrisera BCIP/NBT Plus ALP Substrate (1L)

SKU: AS19 BCIPNBTPLUS-1L|Size: 1000 mL

Agrisera ECL kit (Bright/SuperBright) (100 ml)

SKU: AS16 ECL-SN|Size: 2x 50 mL

Agrisera ECL kit (Bright/SuperBright) (1L)

SKU: AS16 ECL-SN-1L|Size: 2x 500 mL

Agrisera ECL set (Bright/SuperBright) (10 ml trial)

SKU: AS16 ECL-S-N-10|Size: 10 mL

Agrisera ECL set (Bright/SuperBright) (100 ml)

SKU: AS16 ECL-S-N-100|Size: 100 mL

Agrisera ELISA Secondary/ECL/blocking set (trial pack)

SKU: AS19 ELISA-set-10|Size: 1 Each

Agrisera ELISA Secondary/TMB/blocking set (trial pack)

SKU: AS19 ELISATMBset-10|Size: 1 Each

Agrisera HRP-Conjugate/Protein Stabilizer (10 ml)

SKU: AS15 HRPstab-10|Size: 10 mL

Agrisera HRP-Conjugate/Protein Stabilizer (100 ml)

SKU: AS15 HRPstab-100|Size: 100 mL

Agrisera IncuBlocker (chicken antibody)

SKU: AS16 3214|Size: 2x 50 mL

Agrisera IncuBlocker (mouse antibody)

SKU: AS16 3215|Size: 2x 50 mL

Agrisera IncuBlocker (rabbit antibody, 2x100 ml)

SKU: AS16 3111|Size: 2x 100 mL

Agrisera IncuBlocker (rabbit antibody, 2x1L)

SKU: AS16 3111-1L|Size: 2x 1L

Agrisera IncuBlocker (rabbit antibody, 2x20 ml trial pack)

SKU: AS16 3111-20|Size: 2x 20 mL

Agrisera IncuBlocker Wash Buffer (100 ml)

SKU: AS16 3696-100|Size: 100 mL

Agrisera IncuBlocker Wash Buffer (1L)

SKU: AS16 3696-1L|Size: 1 L

Agrisera Secondary/ECL offer

SKU: AS18 SecondaryECL|Size: 1 Each

Agrisera Universal Stabilizer (10 ml)

SKU: AS18 MacroStab-10|Size: 10 mL

Agrisera Universal Stabilizer (100 ml)

SKU: AS18 MacroStab-100|Size: 100 mL

Agrisera Universal Stabilizer (1L)

SKU: AS18 MacroStab-1L|Size: 1 L

Agrisera WestBlock/Secondary/ECL offer

SKU: AS19 WestBlockSecECL|Size: 1 Each

AgriseraECL Bright (10 ml trial pack)

SKU: AS16 ECL-N-10|Size: 2 x 5 mL

AgriseraECL Bright (100 ml)

SKU: AS16 ECL-N-100|Size: 2x 50 mL

AgriseraECL Bright (1L)

SKU: AS16 ECL-N-1L|Size: 2x 500 mL

AgriseraECL Light

SKU: AS24 ECL-M-50|Size: 2 x 25 mL

AgriseraECL SuperBright (10 ml trial pack)

SKU: AS16 ECL-S-10|Size: 2x 5 mL

AgriseraECL SuperBright (100 ml)

SKU: AS16 ECL-S-100|Size: 100 mL

AgriseraECL SuperBright (1L)

SKU: AS16 ECL-S-1L|Size: 2x 500 mL

AgriseraELISA SuperBright (10 ml trial pack)

SKU: AS18 ELISA-ECL-10|Size: 2x 5 mL

AgriseraELISA SuperBright (100 ml)

SKU: AS18 ELISA-ECL-100|Size: 2x 50 mL

AgriseraELISA SuperBright (1L)

SKU: AS18 ELISA-ECL-1L|Size: 2x 500 mL

AgriseraTMB Diluent (100 ml)

SKU: AS15 Diluent|Size: 100 mL

AgriseraTMB HRP Substrate (10 ml)

SKU: AS15 TMB-HRP-10|Size: 10 mL

AgriseraTMB HRP Substrate (100 ml)

SKU: AS15 TMB-HRP-100|Size: 100 mL

AgriseraTMB HRP Substrate (1L)

SKU: AS15 TMB-HRP-1L|Size: 1 L

Albumin (human)

SKU: AS10 1384|Size: 1 mg

Algal Cell Compartment Marker set | 5 Antibodies

SKU: AS18 4247|Size: 1 Each

Alkylphenols (nonylphenol; octylphenol)

SKU: AS13 2733|Size: 0.4 mg

Alpha-1-antichymotrypsin

SKU: AS10 1317|Size: 1 mg

Alpha-mannosidase, Affinity purified

SKU: AS09 650|Size: 1 mg

Alpha1-antichymotrypsin

SKU: AS10 1399|Size: 1 mg

Amyloglucosidase

SKU: AS16 4076|Size: 10 mg

Anti- GLXR | 2-hydroxy-3-oxopropionate reductase

SKU: AS22 4794|Size: 1 Each

Anti- ZEP | Zeaxanthin Epoxidase

SKU: AS23 4947|Size: 50 µg

Anti-12S seed storage protein CRC

SKU: AS23 4990|Size: 1 Each

Anti-14,3,3C | 14,3,3-like protein C

SKU: AS08 317|Size: 100 µL

Anti-14-3-3 GRF | General regulatory element

SKU: AS12 2119|Size: 50 µL

Anti-2S3M | 2S seed storage protein 3 (2S3 Albumin)

SKU: AS20 4404|Size: 200 µg

Recent Breakthroughs

Design, synthesis, and antidiabetic activity of new furan-clubbed 1,2,3-triazole derivatives as <i>α</i>-glucosidase inhibitors.

Devi P, Maity S, Singh A, Mehan S, Singh G, Asati V.

Future Med Chem

PMID:41994872

Free PMC article

Aim The study aims to design, synthesize, and evaluate novel furan-clubbed 1,2,3-triazole derivatives as potential α-glucosidase inhibitors for the management of diabetes mellitus. Materials and methods Ten furan-clubbed-1,2,3-triazole derivatives PD(1-10) were synthesized and characterized through sophisticated instrumentation techniques, including FT-IR, 1 H NMR, 13 C NMR, and LC-MS. The compounds were assessed in vitro for their ability to inhibit the α-glucosidase enzyme. The in vivo antidiabetic effect of the best molecules was evaluated using STZ-nicotinamide induced diabetic mouse model. The observed results were further supported by molecular docking against α-glucosidase (PDB ID: 3L4U) and histopathological examinations. Results The results of in vitro studies showed that the test compound PD-10 exhibited the strongest α-glucosidase inhibition (IC 5 0 = 13.82 μM), outperforming acarbose (IC 5 0 = 32.03 μM), followed by PD-1 and PD-6 . Further, the in vivo antidiabetic evaluation of the best compounds adjudged compound PD-10 as the best molecule among the series. Docking analyses indicated a significant binding affinity of PD-10 (-4.34 kcal/mol). Conclusions The research highlights PD-10 as a promising α-glucosidase inhibitor with strong in vitro and in vivo antidiabetic effects, supported by favorable molecular docking interactions, and emphasizes its potential for development as an antidiabetic lead for further studies and evaluations.

Mechanistic perspectives on antimalarial agents: from FDA-approved drugs to next-generation candidates.

Monika, Sharma B, Awasthi SK.

RSC Adv

PMID:42006802

Free PMC article

Malaria is a major global health challenge, demanding continued innovation in drug discovery and development. This review gives a comprehensive overview of FDA-approved antimalarial drugs and emerging clinical candidates, focusing their chemical structures, mechanisms of action, and molecular targets such as PfATP4, DHFR, DHODH, and PfCRT. The discussion showcases structure-activity relationships, mechanisms underlying drug resistance, and recent advances in structure-guided design of next-generation antimalarials. The review also summarizes the year of approval, mechanistic class, and synthetic origin of key therapeutic agents. Moreover, novel molecules currently in preclinical and clinical trials are discussed in the context of their mode of action, efficacy, and potential for overcoming resistance. Collectively, this article bridges medicinal chemistry insights with biological mechanisms, outlining future directions in the rational design of potent, resistance-resilient antimalarial drugs.

Total chemical synthesis of pentameric cholera toxin subunit B.

Spaltenstein P, Scherer SR, Jones TE, Giesler RJ, Kay MS.

Chem Commun (Camb)

PMID:41891529

Free PMC article

Vibrio cholerae annually infects millions worldwide, causing intense and life-threatening diarrheal disease. The pentameric cholera toxin subunit B (CtxB) binds to the ganglioside GM1 on epithelial cells, initiating endocytosis and downstream toxicity. We present the total chemical protein synthesis of L-CtxB and mirror-image D-CtxB using a three-segment N-to-C native chemical ligation approach. Oxidative folding produced the desired 62 kDa pentameric proteins, with L-CtxB capable of binding native GM1 ligand. Synthetic D-CtxB is now ready to serve as a target in mirror-image phage display, representing a significant milestone for the discovery of toxin-neutralizing D-peptides to treat and prevent cholera.

Can amoxicillin be detected in the aquatic environment? A critical assessment.

Hernández F, Botero-Coy AM, Bijlsma L, Fabregat-Safont D.

Environ Int

PMID:42001666

Free PMC article

Amoxicillin is a broad-spectrum β-lactam antibiotic widely used in both human and veterinary medicine. Following administration, approximately 60-80% of the dose is excreted, largely unmetabolized, via urine within a few hours. Consequently, environmental contamination with amoxicillin, especially in aquatic systems, is a significant concern. Due to its potential ecological risks and the current scarcity of data required for a full assessment, it was included in two consecutive European Union Watch Lists (2018, 2020) of substances for comprehensive monitoring to inform water policy. However, data on amoxicillin levels in aquatic environments are contradictory, ranging from high concentrations in some studies to non-detection in others. The presence of intact amoxicillin in aquatic environments is inherently transient, and the risk of substantial analytical errors in its detection, identification, and quantification is considerable unless stringent methodological precautions are applied. Driven by the need for reliable environmental data, inconsistencies in the existing literature and our own extensive analytical experience, we comprehensively investigated amoxicillin degradation in surface water, influent and effluent wastewater under various conditions. Experiments were conducted under both dark and sunlight conditions using water samples spiked with amoxicillin at 5 μg/L and 50 μg/L. The parent compound was quantified by liquid chromatography-tandem mass spectrometry, whereas transformation products were identified by high-resolution mass spectrometry. By critically assessing the factors that influence the analysis and environmental occurrence of amoxicillin, this study resolves discrepancies in prior reports and clarifies the realistic prospects for its detection. We demonstrate that the parent antibiotic should be rarely found in water samples due to its rapid degradation. Therefore, future monitoring efforts should be focused on its primary degradation product, amoxicillin penicilloic acid, as more reliable indicator of contamination in aquatic environments.

Characterising the urinary metabolome in HIV/TB coinfection and the impact of antiretroviral treatment.

Allen B, Wood R, Luies L.

BMC Infect Dis

PMID:41992151

Free PMC article

Background HIV/TB coinfection poses significant challenges due to complex interactions between both pathogens and the metabolic disruptions they induce. Although antiretroviral treatment (ART) has transformed disease management, its impact on metabolism is not fully understood. Metabolomics offers an in-depth approach to explore the metabolic changes in this coinfected population, providing information into disease mechanisms and the effects of ART. Methods This exploratory study used untargeted urine gas chromatography mass spectrometry metabolomics to profile metabolic alterations in treatment-naïve HIV/TB coinfected patients and those on ART. Healthy controls were included for comparison. Metabolite changes were analysed using univariate statistical methods, including Kruskal-Wallis tests and pairwise comparisons, to identify key metabolites associated with coinfection and ART. Results Findings revealed significant disruptions in several metabolic pathways. Mitochondrial dysfunction was evident, contributing to altered lipid metabolism, impaired energy production, and increased cardiovascular risk. Disruptions in glucose metabolism, including compromised insulin secretion, were observed, alongside evidence of gut dysbiosis linked to inflammation and microbial imbalance. These metabolic disturbances were also associated with increased oxidative stress, reflected in changes to protein metabolism and the development of cachexia. Although ART partially alleviated some metabolic alterations, disruptions remained evident in treated patients. Conclusion This study provides a comprehensive view of the metabolic disturbances in HIV/TB coinfection and the impact of ART. Our findings suggest that persistent mitochondrial dysfunction, altered lipid metabolism, and gut dysbiosis contribute to ongoing metabolic imbalances, underscoring the need for targeted therapeutic strategies to address these challenges.